Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2004Neurodegenerative DiseasesOpen Access

Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s Disease Determined by Protein Biochip Technology

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlessia MaddalenaAzienda Usl Toscana CentroAPAndreas PapassotiropoulosUniversity of BaselCGCharo Gonzalez-AgostiUniversity of Zurich

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Maddalena et al. (2004) studied this question.

synapsesocial.com/papers/6a9e590a9b2dbee2f9368935https://doi.org/10.1159/000080991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation2002 · 274 citations
  2. 2Cerebrospinal fluid A?42 is increased early in sporadic Alzheimer's disease and declines with disease progression1999 · 218 citations
  3. 3Progression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ß40 in Affected Vessels1998 · 184 citations
  4. 4The role of cholesterol in the biosynthesis of β-amyloid.1999 · 323 citations